Get the Stockscreener App
7.22
22.03%
-2.04
After Hours:
8.10
0.88
+12.19%
Clene Inc stock is traded at $7.22, with a volume of 3.44M.
It is down -22.03% in the last 24 hours and down -39.73% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$9.26
Open:
$9.295
24h Volume:
3.44M
Relative Volume:
20.01
Market Cap:
$74.61M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-1.6188
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
-28.87%
1M Performance:
-39.73%
6M Performance:
+84.18%
1Y Performance:
+82.32%
1-Day Range:
$7.21
$9.535
1-Week Range:
$7.21
$10.84
52-Week Range:
$2.2801
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
7.22 | 95.69M | 442.00K | -30.46M | -27.47M | -4.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.13 | 109.90B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.67 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
473.29 | 61.42B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.80 | 56.36B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.78 | 44.06B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 - Investing News Network
D. Boral Capital Maintains Buy Rating for Clene (CLNN) | CLNN St - GuruFocus
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Clene (CLNN) Reports Promising Biomarker Results for ALS Treatme - GuruFocus
Clene Updates on CNM-Au8® ALS Program - TipRanks
Clene announces statistically significant ALS biomarker results - MarketScreener
Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8 - TipRanks
Clene Announces Positive Biomarker Results for CNM-Au8 - TipRanks
Clene Inc Announces Significant ALS Biomarker Results - TradingView
Clene (Nasdaq: CLNN) reports NfL, GFAP drops in ALS as it targets 2026 accelerated NDA - Stock Titan
How Clene Inc. (84C0) stock reacts to new regulationsPortfolio Update Report & Weekly High Potential Stock Alerts - Newser
Why Clene Inc. (84C0) stock stays resilientDay Trade & Community Consensus Trade Alerts - Newser
Will Clene Inc. (84C0) stock see insider accumulation2025 Top Decliners & Daily Risk Controlled Trade Plans - Newser
How analysts revise price targets for Clene Inc. (84C0) stockWall Street Watch & Weekly Top Stock Performers List - Newser
Nanotechnology Stocks To Watch Now – December 1st - Defense World
Clene Inc. (CLNN) 8.53% in After-hours: Plans Update on CNM-Au8 ALS Program - Stocks Telegraph
Clene to Provide CNM-Au8® ALS Program Update - Investing News Network
Clene Inc. to Provide Update on CNM-Au8 Program in ALS during Investor Call on December 3, 2025 - Quiver Quantitative
Clene (Nasdaq: CLNN) to host Dec. 3 CNM-Au8 ALS program update webcast at 8:30 a.m. ET - Stock Titan
Nanotechnology Stocks To Watch NowDecember 1st - MarketBeat
Will Clene Inc. (84C0) stock beat value stocksJuly 2025 Retail & Safe Swing Trade Setups - Newser
Clene Inc. (CLNN) 7.18% in After-hours: Momentum Following Conference Announcement - Stocks Telegraph
Top Nanotechnology Stocks To ConsiderNovember 27th - MarketBeat
Nanotechnology Stocks To ResearchNovember 29th - MarketBeat
Nanotechnology Stocks To Add to Your WatchlistNovember 28th - MarketBeat
Clene Inc. (NASDAQ:CLNN): When Will It Breakeven? - simplywall.st
Top Nanotechnology Stocks To Consider – November 27th - Defense World
Institutions own 17% of Clene Inc. (NASDAQ:CLNN) shares but individual investors control 56% of the company - Yahoo Finance
Is Clene Inc. Equity Warrant stock a safe investment in uncertain marketsTrend Reversal & Smart Allocation Stock Reports - BỘ NỘI VỤ
Clene Inc (CLNN) is looking forward to a strong quarter - Setenews
Best Nanotechnology Stocks To ConsiderNovember 22nd - MarketBeat
Aug Volume: Why Clene Inc. stock remains on buy listsPortfolio Profit Report & Safe Entry Momentum Tips - BỘ NỘI VỤ
Promising Nanotechnology Stocks To Follow TodayNovember 21st - MarketBeat
Best Nanotechnology Stocks To Consider – November 22nd - Defense World
Clene Inc Stock Analysis and ForecastEarnings Growth Projections & Free Rapid Wealth Multiplication - earlytimes.in
Top Nanotechnology Stocks To Keep An Eye OnNovember 19th - MarketBeat
Can Raymed Labs Limited Deliver Stable Cash Flow in Market DownturnsSupport Level Holds & Small Investment Trading Growth - earlytimes.in
Analysts Conflicted on These Consumer Goods Names: Clene (CLNN) and Target (TGT) - The Globe and Mail
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference - Investing News Network
Clene stock holds Buy rating at Benchmark as ALS drug nears FDA submission By Investing.com - Investing.com South Africa
Clene stock holds Buy rating at Benchmark as ALS drug nears FDA submission - Investing.com Canada
Backtesting results for Clene Inc. trading strategiesJuly 2025 Update & Safe Entry Zone Identification - newser.com
Is Clene Inc. Equity Warrant stock supported by strong fundamentals2025 Short Interest & Accurate Technical Buy Alerts - newser.com
Why hedge funds are buying Clene Inc. stockDividend Hike & Growth Oriented Trading Recommendations - newser.com
Is Clene Inc. stock supported by strong cash flowsProduct Launch & Safe Entry Point Alerts - newser.com
Custom watchlist performance reports with Clene Inc.July 2025 Weekly Recap & Weekly Momentum Picks - newser.com
Clene Inc. Equity Warrant stock outlook for YEARPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
Key resistance and support levels for Clene Inc.Layoff News & Smart Swing Trading Techniques - newser.com
Will Clene Inc. (84C0) stock outperform energy sector in 2025Bond Market & AI Powered Market Trend Analysis - newser.com
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):